© Coriolis Pharma

Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.

picture: ©CPC

Which connection method do most industry professionals prefer: tube welding or aseptic connectors? A recent survey revealed their preferences are almost equally split between the two. But that doesn’t mean one method might not be better for your needs.

On 13 April 2021, Evotec SE launched beLAB2122 in collaboration with Bristol-Myers Squibb company and five top-tier academic institutions. Mediated and supported by BioRN Life Science Cluster Rhine-Neckar, this $20 million BRIDGE brings together leading academic institutions in Southwestern Germany with the goal of efficiently advancing novel drug discovery projects.

Picture: Tigermed

The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?

Picture: chfonk/freepik

Company seeks new opportunities for use of mRNA therapeutics.

Picture: 10x Genomics

Just a few years ago, single-cell analyses were complex and not user-friendly. Now, thanks to professionalised workflows, the technology is finding its way into the industry. European Biotechnology spoke with Dr Michael Schnall-Levin, SVP R&D, Founding Scientist, from market leader 10X Genomics about the increasing importance of capturing cell heterogeneity for biomedical research.

Picture: Michael Herdlein

Cellex Group is an experienced facility worldwide for all kind of allogeneic and autologous stem cell collections and is, besides that, growing to become a complete service provider for cellular immunotherapy products. One essential area of the portfolio is Cell Community, the perfect solution for researchers in need of cell products.

Picture: user7350813/freepik

U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022.

Picture: Pharming  Securities

New entrants and variants will be main drivers of the COVID-19 vaccine market as supply gradually begins
to catch up with demand.

Picture: Coriolis Pharma Research

Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands its ATMP development facilities to meet the increasing market demand.